We are analyzing https://link.springer.com/article/10.1602/neurorx.1.2.196.

Title:
Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease | Neurotherapeutics
Description:
Recent advances in understanding the molecular biology of Alzheimer’s disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, pubmed, cas, alzheimers, article, disease, magnetic, resonance, imaging, atrophy, cognitive, mild, brain, neurol, hippocampal, jack, aging, volume, temporal, alzheimer, proton, impairment, normal, spectroscopy, psychiatry, petersen, lobe, mri, regional, medial, neuroradiol, hippocampus, surrogate, kantarci, functional, entorhinal, dementia, adneurology, progression, patients, reson, diseasej, elderly, memory, privacy, cookies, quantitative, markers, early,

Topics {✒️}

brain n-acetyl-l-aspartic acid quantitative magnetic resonance magnetic resonance imaging magnetic resonance scans magnetic resonance microscopy magnetic resonance microimaging n-acetyl-l-aspartate diffusion-weighted mr imaging proton mr spectroscopy increased cerebral myo-inositol mr-based volume measurements jack cr jr mr-based volumetry fluid-registered serial mri functional mr imaging functional brain imaging mri-based hippocampal volume n-acetyl aspartate perfusion mr imaging mild cognitive impairment privacy choices/manage cookies de leon mj dimensional multiphoton imaging registered serial mri article kantarci amino acid metabolites nuclear medicine imaging markers medial temporal lobe serial brain mri amyloid imaging tracers magnetization transfer measurements evidence-based review n-acetylaspartate correlates demented older adults mapping functional mri activation functional imaging brain metabolite concentration modeling brain deformations temporal lobe atrophy cerebral blood flow fox nc regional brain atrophy quantitive nmr measurements medial temporal atrophy jack cr global brain damage semantic memory impairment comparative mr analysis

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease
         description:Recent advances in understanding the molecular biology of Alzheimer’s disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.
         datePublished:
         dateModified:
         pageStart:196
         pageEnd:205
         sameAs:https://doi.org/10.1602/neurorx.1.2.196
         keywords:
            Alzheimer’s disease
            surrogate marker
            magnetic resonance imaging
            magnetic resonance spectroscopy
            mild cognitive impairment
            volumetry
            Neurosciences
            Neurology
            Neurosurgery
            Neurobiology
         image:
         isPartOf:
            name:NeuroRX
            issn:
               1545-5343
            volumeNumber:1
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Kejal Kantarci
               affiliation:
                     name:Mayo Clinic
                     address:
                        name:Department of Radiology, Mayo Clinic, Rochester
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Clifford R. Jack
               affiliation:
                     name:Mayo Clinic
                     address:
                        name:Department of Radiology, Mayo Clinic, Rochester
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease
      description:Recent advances in understanding the molecular biology of Alzheimer’s disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.
      datePublished:
      dateModified:
      pageStart:196
      pageEnd:205
      sameAs:https://doi.org/10.1602/neurorx.1.2.196
      keywords:
         Alzheimer’s disease
         surrogate marker
         magnetic resonance imaging
         magnetic resonance spectroscopy
         mild cognitive impairment
         volumetry
         Neurosciences
         Neurology
         Neurosurgery
         Neurobiology
      image:
      isPartOf:
         name:NeuroRX
         issn:
            1545-5343
         volumeNumber:1
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Kejal Kantarci
            affiliation:
                  name:Mayo Clinic
                  address:
                     name:Department of Radiology, Mayo Clinic, Rochester
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Clifford R. Jack
            affiliation:
                  name:Mayo Clinic
                  address:
                     name:Department of Radiology, Mayo Clinic, Rochester
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:NeuroRX
      issn:
         1545-5343
      volumeNumber:1
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic
      address:
         name:Department of Radiology, Mayo Clinic, Rochester
         type:PostalAddress
      name:Mayo Clinic
      address:
         name:Department of Radiology, Mayo Clinic, Rochester
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Kejal Kantarci
      affiliation:
            name:Mayo Clinic
            address:
               name:Department of Radiology, Mayo Clinic, Rochester
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Clifford R. Jack
      affiliation:
            name:Mayo Clinic
            address:
               name:Department of Radiology, Mayo Clinic, Rochester
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Radiology, Mayo Clinic, Rochester
      name:Department of Radiology, Mayo Clinic, Rochester

External Links {🔗}(278)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.55s.

LINK . SPRINGER . COM {}